Low-molecular weight proteins in end-stage renal disease: potential toxicity and dialytic removal mechanisms.
Low-molecular-weight proteins (LMWP) are now recognized as a distinct class of uremic toxins, and numerous compounds in this category have been identified. Dr. Henderson has spent much of his career investigating ways to enhance the removal of intermediate- and large-sized uremic retention molecules. As LMWP clearly fall under this category, it is fitting to provide a review of several aspects of this molecular class. Normal renal metabolism of LMWP is discussed along with the changes that occur during chronic renal insufficiency. The effect of end-stage renal disease on plasma LMWP concentrations is assessed. As examples of the potential uremic toxicity of this molecular class, leptin, adrenomedullin, and the compounds associated with increased susceptibility to infection are highlighted. Finally, an overview of LMWP removal mechanisms for both hemodialysis and the convective therapies is provided.
Clark
William R
WR
Renal Division, Baxter Healthcare Corporation, McGaw Park, Indiana, USA. clarkbi@baxter.com
Gao
Dayong
D
D017583:Hemodiafiltration; D006440:Hemofiltration; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000209:etiology*; D008970:Molecular Weight; D011506:Proteins / Q000737:chemistry* / Q000378:metabolism*; D006435:Renal Dialysis
D011506:Proteins